Oncology
Showing 1-6 of 6 Results
-
Sheila Lahijani, MD, FACLP
Clinical Professor, Psychiatry and Behavioral Sciences - Medical Psychiatry
Clinical Professor (By courtesy), Medicine - OncologyBioDr. Lahijani is a Clinical Professor of Medical Psychiatry and, by courtesy, Oncology, at Stanford University School of Medicine and a nationally recognized leader in psycho-oncology. With extensive training and expertise in internal medicine, psychiatry, and consultation-liaison psychiatry, she has made significant contributions to the integration of psychiatric care within oncological settings.
Since her appointment at Stanford in 2015, Dr. Lahijani has served as the lead psychiatric oncologist at the Stanford Cancer Center, where she provides medical psychiatric consultation services and collaborates with interdisciplinary teams to enhance patient outcomes. In her capacity as Medical Director of the Stanford Cancer Center Psychosocial Oncology Program, a position she has held since 2019, she is responsible for the strategic development and implementation of comprehensive psychiatric services tailored to the unique needs of patients with cancer.
Additionally, Dr. Lahijani serves as the Section Chief of Psycho-Oncology in the Division of Medical Psychiatry where she oversees psych-onc faculty development and leads the training of medical psychiatry fellows in psycho-oncology. She also supervises advanced practice providers while also working as an attending psychiatric oncologist to provide care for patients with complex medical and psychiatric comorbidities across all hematology and oncology units.
Dr. Lahijani's academic credentials include her graduation from Brown Medical School, followed by the completion of a combined residency in Internal Medicine and Psychiatry at Rush University Medical Center. After completing residency, she practiced internal medicine and psychiatry with a focus on triple diagnosis (HIV, addiction medicine, mental health). She then further advanced through a Psychosomatic Medicine Fellowship at Northwestern University's Feinberg School of Medicine, during which time she received specialized training in psychiatric oncology at the Lurie Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center.
Her clinical expertise encompasses psychopharmacology and a range of treatment modalities, including Meaning Centered Psychotherapy and Dignity Therapy. Dr. Lahijani is deeply committed to fostering relationship-centered skills and promoting provider wellness. As a faculty member of Advancing Communication Excellence at Stanford, she has led workshops designed to enhance communication competencies among faculty and staff.
Dr. Lahijani's scholarly pursuits are at the intersection of medicine and psychiatry, with a particular emphasis on the neuropsychiatric sequelae of cancer treatment, innovations in care, and medical education. She is dedicated to the education and mentorship of trainees in Psychiatry, Internal Medicine, Hematology/Oncology, and Neurology. Through her commitment to academic excellence, Dr. Lahijani plays a pivotal role in preparing the next generation of healthcare providers to adeptly navigate the intricate and multifaceted needs of patients and their caregivers, thereby promoting a comprehensive approach to patient care. -
Ronald Levy, MD
Robert K. and Helen K. Summy Professor in the School of Medicine
Current Research and Scholarly InterestsClinical Interests: lymphoma. Research Interests: Immunology and molecular biology of lymphoid malignancy; molecular vaccines for cancer.
-
Michael Lim, M.D.
Stanford Medicine Endowed Chair of the Department of Neurosurgery, Professor of Neurosurgery and, by courtesy, of Radiation Oncology, of Medicine, of Otolaryngology - Head & Neck Surgery (OHNS) and of Neurology and Neurological Sciences
BioDr. Lim is the Chair of the Department of Neurosurgery and a board-certified neurosurgeon specializing in brain tumors and trigeminal neuralgia.
Dr. Lim’s clinical interests include the treatment of benign and malignant brain tumors, with special interest in gliomas, meningiomas, metastatic tumors, and skull base tumors. Dr. Lim also specializes in surgical treatments for trigeminal neuralgia. During his time at Johns Hopkins, Dr. Lim built one of the largest brain tumor and trigeminal neuralgia practices and utilized the most advanced surgical technologies and techniques for his patients. As a passionate voice for patient experience, he has been recognized by his peers and patients for his integrity and compassionate care, including a Service Excellence Award from HealthNetwork Foundation.
As a mentor, he has garnered numerous teaching awards, including being honored as an outstanding teacher by Johns Hopkins University School of Medicine. He is actively involved in shaping education for neurosurgery and oncology across the United States and around the world. He is the recipient of the prestigious 2023 Abhijit Guha Award in Neuro-Oncology.
Dr. Lim’s research interests focus on harnessing the immune system to fight cancer. His laboratory focuses on understanding mechanisms of immune evasion by cancer cells. He has successfully translated his findings from the laboratory to the clinics and has conducted and led several large national immunotherapy clinical trials for brain tumors.
Dr. Lim’s bibliography contains well over 300 articles on topics such as immunotherapy for glioblastoma, long-term survival of glioma patients treated with stereotactic radiation, and treatment of neuropathic pain. His work has appeared in Science Translational Medicine, Clinical Cancer Research, Lancet Oncology, Nature Immunology, and many more publications. He also has written 20 book chapters and monographs.
Dr. Lim is a world leader in immunotherapy for brain tumors. In addition to being invited world-wide to give lectures and seminars, he has given platform presentations on the topics of immunotherapy for brain tumors, neurosurgical techniques and management of brain tumors at the American Society of Clinical Oncologists, American Academy of Neurological Surgeons, Radiological Society of North America, Annual Symposium on Brain and Spine Metastases, Congress of Neurological Surgeons, and other meetings. In addition, he has served as platform chairman of the CNS session at the American Society for Clinical Oncology conference.
Dr. Lim is a member of the American Society for Clinical Oncology, Congress of Neurological Surgeons, American Association of Neurological Surgeons, and Society for Neuro-Oncology. Dr. Lim served as the program co-chair of the Society for Neuro-Oncology and CNS section of the American Society for Clinical Oncology. He also served on many executive committees, including the Executive Committee for the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons.
Trigeminal neuralgia treatment: https://www.youtube.com/watch?v=-n8nvwkwZik
Trigeminal neuralgia patient stories: https://www.youtube.com/watch?v=kClePRPYlQs&t=1s -
Janice Lu
Clinical Professor, Medicine - Oncology
BioDr. Janice Lu is Clinical Professor of Medicine in the Division of Medical Oncology at Stanford University School of Medicine. She specializes in the treatment of breast cancer, with expertise in hormone receptor–positive and HER2-positive disease, antibody-drug conjugates, and immunotherapy. Dr. Lu has led and contributed to multiple clinical trials, including playing a key role in the EMERALD trial, which resulted in FDA approval of the first oral SERD for ESR1-mutated ER+/HER2- metastatic breast cancer. Her translational research focuses on liquid biopsy, epigenetics, AI and multiomics approaches to treatment resistance. She has chaired national sessions on precision oncology and holds leadership roles with NRG Oncology and ASCO, including Vice-Chair of the NRG Immunotherapy Subcommittee and Track Leader for ASCO’s Developmental Therapeutics and Targeted Therapy Education Program. She has also served on committees for the National Comprehensive Cancer Network (NCCN) and the Southwest Oncology Group (SWOG).
Dr. Lu completed her Hematology and Oncology fellowship at New York University School of Medicine and earned a PhD in epigenetics under the mentorship of late Dr. David Allis, a pioneer in the field and 2018 Lasker Laureate. Prior to joining Stanford, she was Director of Breast Medical Oncology and led the Circulating Tumor Cell (CTC) Core Lab at Northwestern University Feinberg School of Medicine, before returning to the Bay Area to be with her family and to further expand research and patient-centered care.
